Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany believes that, although CAR-T therapies may never completely replace transplant, the focus should be on the correct identification of patients who need either treatment, particularly in the myeloma setting. Patient characteristics such as age should be taken into consideration to make better clinical decisions, always relying on both therapeutical options. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.